3-Ethyl-9-methoxy-9-methyl-3-(2-propoxyethoxy)-2,4,8,10-tetraoxaspiro[5.5]undecane

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-Ethyl-9-methoxy-9-methyl-3-(2-propoxyethoxy)-2,4,8,10-tetraoxaspiro[5.5]undecane
• 英文别名: 3-ethyl-9-methoxy-9-methyl-3-(2-propoxyethoxy)-2,4,8,10-tetraoxaspiro[5.5]undecane
• 化学式: C₁₆H₃₀O₇
• 分子量: 334.4
• InChiKey: VSNMZTBASUMJLO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  23
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  64.6
• 氢给体数：
  0
• 氢受体数：
  7

文献信息

• US20140275046A1
  申请人：——

  公开号：US20140275046A1

  公开（公告）日：2014-09-18
• COMPOSITIONS OF A POLYORTHOESTER AND AN APROTIC SOLVENT
  申请人：Heron Therapeutics, Inc.

  公开号：US20140296282A1

  公开（公告）日：2014-10-02

  Delivery systems and compositions comprised of a biodegradable polyorthoester polymer, an aprotic solvent, and a drug are described. The solvent is selected to modulate release of drug from the composition, where, in some embodiments, the solvent is rapidly released after administration and provides a corresponding rapid rate of drug release. Alternatively, in other embodiments, the solvent is slowly released from the composition after its administration, and provides a correspondingly slow rate of drug release.
• US20140275145A1
  申请人：——

  公开号：US20140275145A1

  公开（公告）日：2014-09-18
• COMPOSITIONS OF A POLYORTHOESTER AND AN ORGANIC ACID EXCIPIENT
  申请人：Heron Therapeutics, Inc.

  公开号：US20150297730A1

  公开（公告）日：2015-10-22

  Delivery systems and compositions comprised of a biodegradable polyorthoester polymer, an organic acid excipient, and a basic drug are described, along with related methods.
• PHARMACEUTICAL COMPOSITION COMPRISING ANTIEMETIC COMPOUNDS AND POLYORTHOESTER
  申请人：HERON THERAPEUTICS, INC.

  公开号：US20150320866A1

  公开（公告）日：2015-11-12

  The present disclosure provides for sustained release pharmaceutical formulations which can deliver both a 5-hydroxytryptamine 3 (5HT3) receptor antagonist and a neurokinin-1 (NK1) receptor antagonist to a subject in need thereof. Formulations described herein are suitable for subcutaneous administration. Also described are methods of treatment of various disorders, including chemotherapy-induced nausea and vomiting (CINV). The disclosed compositions and methods provide for less frequent dosing of the therapeutic agents, thereby increasing subject comfort and compliance.